Instil Bio Inc. (TIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Instil Bio Inc. (TIL) has a cash flow conversion efficiency ratio of -0.062x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.08 Million) by net assets ($113.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Instil Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Instil Bio Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Instil Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Instil Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
0.033x |
|
Metair
JSE:MTA
|
-0.172x |
|
Kronos Bio Inc
NASDAQ:KRON
|
-0.161x |
|
Top High Image
TWO:3284
|
-0.004x |
|
Airmate Cayman International Co Ltd
TW:1626
|
0.007x |
|
Botnia Gold AB (publ)
ST:BOTX
|
0.446x |
|
Kingston Resources Ltd
AU:KSN
|
0.081x |
|
Wiener Privatbank SE
VI:WPB
|
-0.422x |
Annual Cash Flow Conversion Efficiency for Instil Bio Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Instil Bio Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Instil Bio Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $113.87 Million | $-36.62 Million | -0.322x | +2.17% |
| 2024-12-31 | $169.44 Million | $-55.70 Million | -0.329x | +9.50% |
| 2023-12-31 | $225.83 Million | $-82.03 Million | -0.363x | +26.69% |
| 2022-12-31 | $363.61 Million | $-180.16 Million | -0.495x | -125.24% |
| 2021-12-31 | $555.20 Million | $-122.14 Million | -0.220x | -117.17% |
| 2020-12-31 | $292.37 Million | $-29.62 Million | -0.101x | +84.58% |
| 2019-12-31 | $8.06 Million | $-5.29 Million | -0.657x | -- |
About Instil Bio Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as … Read more